Epigenetics and genetics in endometrial cancer: New carcinogenic mechanisms and relationship with clinical practice

Epigenomics

Volumn 4, Issue 2, 2012, Pages 147-162

  Banno, Kouji ^a   Kisu, Iori ^a   Yanokura, Megumi ^a   Masuda, Kenta ^a   Ueki, Arisa ^a   Kobayashi, Yusuke ^a   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

DNA hypermethylation; DNA mismatch repair; endometrial cancer; epimutation; HDAC inhibitor; hMLH1; lower uterine segment; Lynch syndrome; miRNA; MMR

Indexed keywords

APC PROTEIN; CATECHOL METHYLTRANSFERASE; FLICE INHIBITORY PROTEIN; G PROTEIN COUPLED RECEPTOR 54; HISTONE DEACETYLASE INHIBITOR; HOX PROTEIN; MICRORNA; MISMATCH REPAIR PROTEIN PMS2; PROTEIN; PROTEIN MLH1; PROTEIN MLH3; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P73; PROTEIN PMS1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RSK4 PROTEIN; SPROUTY PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG; UVOMORULIN;

AGE; CANCER CELL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER SCREENING; CARCINOGENESIS; CLINICAL PRACTICE; COWDEN SYNDROME; DNA METHYLATION; ENDOMETRIUM CANCER; EPIGENETICS; FAMILIAL CANCER; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MOLECULAR MECHANICS; ONCOGENE; PEUTZ JEGHERS SYNDROME; PREDICTION; PRIORITY JOURNAL; REVIEW;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; EPIGENOMICS; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICRORNAS; NUCLEAR PROTEINS;

EID: 84859203367     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.13     Document Type: Review

References (120)

1. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
2. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann. Surg. 234 (1), 10-20 (2001).
3. Muraki Y, Banno K, Yanokura M et al. Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). Oncol. Rep. 22(5), 967-972 (2009). Recent comprehensive review of endometrial cancer epigenetic DNA hypermethylation.
4. Velasco A, Pallares J, Santacana M et al. Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Hum. Pathol. 42 (2), 185-193 (2011).
5. Pallares J, Velasco A, Eritja N et al. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod. Pathol. 21(6), 691-699 (2008).
6. Kang HS, Baba T, Mandai M et al. GPR54 is a target for suppression of metastasis in endometrial cancer. Mol. Cancer Ther. 10 (4), 580-590 (2011).
7. Yi TZ, Guo J, Zhou L et al. Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. Cancer Invest. 29(1), 86-92 (2011).
8. Dewdney SB, Rimel BJ, Thaker PH et al. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin. Cancer Res. 17(8), 2120-2129 (2011).
9. Kawaguchi M, Banno K, Yanokura M et al. Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. Int. J. Oncol. 35(5), 977-982 (2009).
10. Ignatov A, Bischoff J, Ignatov T et al. APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci. 101(2), 321-327 (2010).
11. Satoh A, Toyota M, Itoh F et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63(24), 8606-8613 (2003).
12. Wang X, Yang Y, Xu C et al. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel. Int. J. Gynecol. Cancer 21(6), 996-1003 (2011).
13. Lo TL, Yusoff P, Fong CW et al. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res. 64(17), 6127-6136 (2004).
14. Sutterluty H, Mayer CE, Setinek U et al. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol. Cancer Res. 5(5), 509-520 (2007).
15. Fong CW, Chua MS, McKie AB et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 66(4), 2048-2058 (2006).
16. Holliday R. The inheritance of epigenetic defects. Science 238(4824), 163-170 (1987).
17. Schofield PN, Joyce JA, Lam WK et al. Genomic imprinting and cancer; new paradigms in the genetics of neoplasia. Toxicol. Lett. 120(1-3), 151-160 (2001).
18. Peltomäki P. Lynch syndrome genes. Fam. Cancer 4(3), 227-232 (2005).
19. Kondo E, Furukawa T, Yoshinaga K et al. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int. J. Oncol. 17(3), 535-541 (2000).
20. Banno K, Yanokura M, Kawaguchi M et al. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int. J. Oncol. 31(4), 713-720 (2007).
21. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 36(5), 497-501 (2004).
22. Hitchins MP, Wong JJ, Suthers G et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N. Engl. J. Med. 356(7), 697-705 (2007).
23. Goel A, Nguyen TP, Leung HC et al. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int. J. Cancer 128(4), 869-878 (2011).
24. Chan TL, Yuen ST, Kong CK et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 38(10), 1178-1183 (2006). First report of epimutation of the hMSH2 gene in Lynch syndrome.
25. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31(11), 1913-1921 (2010).
26. Ligtenberg MJ, Kuiper RP, Chan TL et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat. Genet. 41(1), 112-117 (2009).
27. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 68(7), 2094-2105 (2008).
28. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31(5), 766-776 (2010).
29. Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J. Neurooncol. 90(1), 1-7 (2008).
30. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun. 379(3), 726-731 (2009).
31. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int. J. Cancer 127(5), 1072-1080 (2010).
32. Huang YW, Liu JC, Deatherage DE et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 69(23), 9038-9046 (2009).
33. Tsuruta T, Kozaki KI, Uesugi A et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 71(20), 6450-6462 (2011). Striking report demonstrating the tumor suprressor effect of miR-152 against endometrial cancer in vivo and in vitro.
34. Stumpel DJ, Schotte D, Lange-Turenhout EA et al. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia 25(3), 429-439 (2011).
35. Chen Y, Song Y, Wang Z et al. Altered expression of miR-148a and miR-152 in gastrointestinal cancers and its clinical significance. J. Gastrointest. Surg. 14(7), 1170-1179 (2010).
36. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51(3), 881-890 (2010).
37. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9(11), 785-797 (2009).
38. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11(12), 834-848 (2010).
39. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol. Cancer 9, 57 (2010).
40. Guertin DA, Stevens DM, Saitoh M et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15(2), 148-159 (2009).
41. Dakalakis M, Nguyen TT, Nguen C et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxy cytidine (decitabine) treatment. Blood 100(8), 2957-2964 (2002).
42. Issa JP, Garcia-Manero G, Giles FJ. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine(decitabine) in hematopoietic malignancies. Blood 103(5), 1635-1640 (2004).
43. Satoh A, Toyota M, Itoh F. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63(24), 8606-8613 (2003).
44. Scolnick DM, Halazonetis TD. Chfr defines amitotic stress checkpoint that delays entry into metaphase. Nature 406(6794), 430-435 (2000).
45. Kang D, Chen J, Wong J. The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J. Cell Biol. 156(2), 249-259 (2002).
46. Yu X, Minter-Dykhouse K, Malureanu L. Chfr is required for tumor suppression and Aurora A regulation. Nat. Genet. 37(4), 401-406 (2005).
47. Toyota M, Sasaki Y, Satoh A. Epigenetic inactivation of CHFR in human tumors. Proc. Natl Acad. Sci. USA 100(13), 7818-7823 (2003). Highly significant finding about the CHFR gene, relevant to the biomarker for chemosinsitivity to taxane.
48. Ogi K, Toyota M, Mita H. Small interfering RNA-induced CHFR silencing sinsitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol. Ther. 4(7), 773-780 (2005).
49. Koga Y, Kitajima Y, Miyoshi A. The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J. Gastroenterol. 41(2), 133-139 (2006).
50. Jenuwein T, Allis CD. Translating the histone code. Science 293(5532), 1074-1080 (2001).
51. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23(17), 3971-3993 (2005).
52. Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, Alfer J. Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum. Reprod. 22(11), 2956-2966 (2007).
53. Weichert W, Denkert C, Noske A et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10(9), 1021-1027 (2008).
54. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101(12), 2760-2770 (2004).
55. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. USA 101(5), 1241-1246 (2004).
56. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 7(4), 583-598 (2007).
57. Takai N, Narahara H. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr. Med. Chem. 14(24), 2548-2553 (2007). Recent review highlighting the histone deacetylase inhibitors to endometrial cancer.
58. Uchida H, Maruyama H, Ngashima T, Asada H, Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycoderin. Endocrinology 146(129), 5365-5373 (2005).
59. Sandor V, Robbins AR, Robey R, Myers T. FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 11(6), 445-454 (2011).
60. Dowdy SC, Jiang S, Zhou XC et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther. 5(11), 2767-2776 (2006).
61. Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest. New Drugs 25(2), 131-138 (2007).
62. Modesitt SC, Sill M, Hoffman JS, Bender DP. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109(2), 182-186 (2008).
63. Takai N, Desmond JC, Kumagai T et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 10(3), 1141-1149 (2004).
64. Takai N, Ueda T, Nishida M et al. CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Oncology 70(2), 97-105 (2006).
65. Takai N, Ueda T, Nishida M, Nasu, K, Narahara H. A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int. J. Mol. Med. 17(2), 323-329 (2006).
66. Terao Y, Nishida J, Horiuchi S et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int. J. Cancer 94(2), 257-267 (2001).
67. Jiang S, Dowdy SC, Meng XW et al. Histone deacetylase inhibitors induce apoptosis in both type I and type II endometrial cancer cells. Gynecol. Oncol. 105(2), 493-500 (2007).
68. Jung M, Brosch G, Kölle D, Scherf H, Gerhäuser C, Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 42(22), 4669-4679 (1999).
69. Ueda T, Takai N, Nishida M, Nasu K, Narahara H. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int. J. Mol. Med. 19(2), 301-308 (2007).
70. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6), 1453-1456 (1999). First report of the revised clinical criteria for Lynch syndrome.
71. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 138(7), 2197.e1-2197.e7 (2010).
72. Hampel H, Panescu J, Lockman J et al. Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 67(19), 9603 (2007).
73. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 16(1), 14-22 (2009).
74. Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum. Mol. Genet. 6(1), 105-110 (1997).
75. Vasen HF, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110(4), 1020-1027 (1996).
76. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition - update of ICG-HNPCC/INSiGHT mutation database. Dis. Markers 20(4-5), 269-276 (2004).
77. Schweizer P, Moisio AL, Kuismanen SA et al. Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer. Cancer Res. 61(7), 2813-2815 (2001).
78. Banno K, Susumu N, Hirao T et al. Identification of germline MSH2 gene mutations in endometrial cancer not fulfilling the new clinical criteria for hereditary nonpolyposis coloretcal cancer. Cancer Genet. Cytogenet. 146(1), 58-65 (2003).
79. Broaddus RR, Lynch HT, Chen LM et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106(1), 87-94 (2006).
80. Vasen HF, Watson P, Mecklin JP et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res. 14(4B), 1675-1678 (1994).
81. Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HF. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int. J. Cancer 102(2), 198-200 (2002).
82. Hampel H, Frankel W, Panescu J et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 66(15), 7810-7817 (2006).
83. Hirai Y, Banno K, Suzuki M et al. Molecular epidemiological and mutational analysis of DNA mismatch repair (MMR) genes in endometrial cancer patients with HNPCC-associated familial predisposition to cancer. Cancer Sci. 99(9), 1715-1719 (2008). Notable report demonstrating the responsibility of hMSH6 in Lynch syndrome-associated endometrial cancer.
84. Banno K, Yanokura M, Kobayashi Y et al. Endometrial cancer as a familial tumor: pathology and molecular carcinogenesis (review). Curr. Genomics 10(2), 127-132 (2009).
85. Lancaster JM, Powell CB, Kauff ND et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol. 107(2), 159-162 (2007).
86. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58(22), 5248-5257 (1998).
87. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17(18), 2413-2417 (1998).
88. Resnick KE, Hampel H, Fishel R, Cohn DE. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol. Oncol. 114(1), 128-134 (2009).
89. Lindor NM, Petersen GM, Hadley DW et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296(12), 1507-1517 (2006).
90. Vasen HF, Moslein G, Alonso A et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J. Med. Genet. 44(6), 353-362 (2007).
91. Ollikainen M, Abdel-Rahman WM, Moisio AL et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J. Clin. Oncol. 23(21), 4609-4616 (2005).
92. Jacques SM, Qureshi F, Ramirez NC, Malviya VK, Lawrence WD. Tumors of the uterine isthmus: Clinicopathologic features and immunohistochemical characterization of p53 expression and hormone receptors. Int. J. Gynecol. Pathol. 16(1), 38-44 (1997).
93. Westin S, Lacour R, Urbauer D et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J. Clin. Oncol. 26(36), 5965-5971 (2008). Striking report demonstrating the association between cancer of the lower uterine segment and Lynch syndrome.
94. Masuda K, Banno K, Yanokura M et al. Carcinoma of the lower uterine segment (LUS): clinicopathological characteristics and association with lynch syndrome. Curr. Genomics 12(1), 25-29 (2011).
95. Hachisuga T, Kaku T, Enjoji M. Carcinoma of the lower uterine segment. Clinicopathologic analysis of 12 cases. Int. J. Gynecol. Pathol. 8(1), 26-35 (1989).
96. Watanabe Y, Nakajima H, Nozaki K et al. Clinicopathologic and immunohistochemical features and microsatellite status of endometrial cancer of the uterine isthmus. Int. J. Gynecol. Pathol. 20(4), 368-373 (2001).
97. Nelen MR, Kremer H, Konings IB et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur. J. Hum. Genet. 7(3), 267-273 (1997).
98. Nelen MR, Padberg GW, Peeters EA et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat. Genet. 13(1), 114-116 (1996).
99. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16(1), 64-67 (1997).
100. Salem OS, Steck WD. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J. Am. Acad. Dermatol. 8(5), 686-696 (1983).
101. Higuchi M, Onishi K, Kikuchi C, Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat. Cell Biol. 10(1), 1356-1364 (2008).
102. Black D, Bogomolniy F, Robson ME, Pffit K, Barakat RR, Boyd J. Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol. Oncol. 96(1), 1-24 (2005).
103. +/- mice. Cancer Res. 60(13), 3605-3611 (2000).
104. Sardinoux M, Raingeard I, Bessis D, Coupier I, Renard E, Bringer J. Cowden syndrome, or multiple hamartomatous tumor syndrome, in clinical endocrinology. Ann. Endocrinol. 71(4), 264-273 (2010).
105. Farooq A, Walker LJ, Bowling J, Audisio RA. Cowden syndrome. Cancer Treat. Rev. 36(8), 577-583 (2010).
106. Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Semin. Oncol. 34(5), 428-434 (2007).
107. Schmeler KM, Daniels MS, Brandt AC, Lu KH. Endometrial cancer in an adolescent: a possible manifestation of Cowden syndrome. Obstet. Gynecol. 114(2), 477-479 (2009).
108. Beggs AD, Latchford AR, Vasen HF et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 59(7), 975-986 (2010).
109. Scully RE. Sex cord tumor with annular tubules a distinctive ovarian tumor of the Peutz-Jeghers syndrome. Cancer 25(5), 1107-1121 (1970).
110. Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6), 1447-1453 (2000).
111. Conteras CM, Gurumurthy S, Haynie JM et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 68(3), 759-766 (2008).
112. Kondi-Pafiti A, Bakalianou K, Iavazzo C, Dastamani C, Hasiakos D, Liapis A. Endometrial carcinoma and ovarian sex cord tumor with annular tubules in a patients with history of Peutz-Jegers syndrome and multiple malignancies. Eur. J. Gynaecol. Oncol. 32(49), 452-454 (2011).
113. Pleasance ED, Cheetham RK, Stephense PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278), 191-196 (2009).
114. Pleasance ED, Stephens PJ, O'Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463(7278), 184-190 (2009).
115. Cancer Genome Atlas Research Network. comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061-1068 (2008).
116. Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian carcinoma. Nature 474(7353), 609-615 (2011)
117. The International Cancer Genome Consortium. International network of cancer genome projects. Nature 464(7291) 993-998 (2010).
118. Takai N, Narahara H. Array-based approach for the identification of epigenetic silenced tumor suppressor genes. Curr. Genomics 9(1), 22-24 (2008).
119. The Cancer Genome Atlas.http://cancergenome.nih.gov
120. International Cancer Genome Consortium.www.icgc.org